Serum protein expression profiling for cancer detection: validation of a SELDI-based approach for prostate cancer.


Multiple studies have reported that analysis of serum and other bodily fluids using surface enhanced laser desorption/ionization time of flight mass spectroscopy (SELDI-TOF-MS) can identify a "fingerprint" or "signature" of spectral peaks that can separate patients with a specific disease from normal control patients. Ultimately, classification by SELDI-TOF-MS relies on spectral differences in position and amplitude of resolved peaks. Since the reproducibility of quantitation, resolution and mass accuracy of the SELDI-TOF-MS, or any high throughput mass spectrometric technique, has never been determined this method has come under some skepticism as to its clinical usefulness. This manuscript describes a detailed design of a three-phase study to validate the clinical usefulness of SELDI-TOF-MS in the identification of patients with prostatic adenocarcinoma (PCA). At the end of this validation study, the usefulness of the general SELDI-TOF-MS approach to identifying patients with PCA will be demonstrated and how it compares with PCA diagnosis by measuring prostate specific antigen.


One protocol is associated with this publication:

  • Adam BL
  • Bigbee WL
  • Carroll C
  • Conrads TP
  • Feng Z
  • Grizzle WE
  • Izbicka E
  • Jendoubi M
  • Johnsey D
  • Kagan J
  • Leach RJ
  • McCarthy DB
  • Semmes OJ
  • Srivastava S
  • Srivastava S
  • Thompson IM
  • Thornquist MD
  • Verma M
  • Zhang Z
  • Zou Z
PubMed ID
Appears In
Dis Markers, 19 (4-5)